Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens.

IF 1.6 4区医学 Q3 OPHTHALMOLOGY

Optometry and Vision Science Pub Date : 2025-03-25 DOI:10.1097/OPX.0000000000002244

Paul Chamberlain, David S Hammond, Arthur Bradley, Baskar Arumugam, Kathryn Richdale, John McNally, Chris Hunt, Graeme Young

{"title":"Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens.","authors":"Paul Chamberlain, David S Hammond, Arthur Bradley, Baskar Arumugam, Kathryn Richdale, John McNally, Chris Hunt, Graeme Young","doi":"10.1097/OPX.0000000000002244","DOIUrl":null,"url":null,"abstract":"Significance: This 7-year clinical study assessed the impact of age and number of years of myopia control treatment with MiSight 1 day (omafilcon A; CooperVision, Inc., Pleasanton, CA) dual-focus contact lenses on post-treatment eye growth and myopia progression. Growth and progression after treatment were ceased and returned to age-normal levels retaining prior accrued treatment gains.Purpose: This study aimed to assess eye growth and refractive changes after cessation of prolonged myopia control treatment with a dual-focus contact lens.Methods: Eighty-three subjects completing a 6-year clinical trial of a dual-focus myopia control contact lens (MiSight 1 day) continued into a follow-on 1-year \"wash-out\" phase in which all subjects were fit with a single-vision contact lens (Proclear 1 day, omafilcon A; CooperVision, Inc.). Right and left eye data were analyzed from 38 subjects with 6 years of prior treatment (T6) and 40 receiving treatment during study years 4 to 6 (T3). Axial length and cyclopleged spherical equivalent refractive errors were monitored annually for 7 years. Expected axial growth and myopia progression during years 4 to 7 if treatment had not been started were estimated by extrapolating growth of untreated myopic control eyes collected during years 1 to 3 using population-based estimates of age effects on growth rates.Results: During the untreated year 7, annualized axial growth and refractive changes were 0.09 ± 0.09 (T3) and 0.10 ± 0.10 mm/y (T6), and -0.23 ± 0.36 (T3) and -0.21 ± 0.40 D/y (T6), respectively, each slightly greater than observed during the previous year of treatment (0.07 ± 0.12 [T3] and 0.08 ± 0.07 mm [T6], and -0.04 ± 0.34 [T3] and -0.13 ± 0.42 D [T6]). Year 7 progression was less for the older (11 to 12 at baseline, -0.17 ± 0.40 D/0.05 ± 0.07 mm) than the younger (8 to 10 at baseline, -0.26 ± 0.36 D/0.13 ± 0.10 mm) subgroup. Years in treatment (3 vs. 6) did not influence post-treatment growth or progression.Conclusions: A cessation study following 3 or 6 years of myopia control treatment with the dual-focus myopia control contact lens found axial growth and myopia progression rates similar to those expected of untreated myopic eyes at these ages. This finding reveals that accrued treatment gains were retained and neither amplified nor diminished after cessation of treatment.","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Optometry and Vision Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/OPX.0000000000002244","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Significance: This 7-year clinical study assessed the impact of age and number of years of myopia control treatment with MiSight 1 day (omafilcon A; CooperVision, Inc., Pleasanton, CA) dual-focus contact lenses on post-treatment eye growth and myopia progression. Growth and progression after treatment were ceased and returned to age-normal levels retaining prior accrued treatment gains.

Purpose: This study aimed to assess eye growth and refractive changes after cessation of prolonged myopia control treatment with a dual-focus contact lens.

Methods: Eighty-three subjects completing a 6-year clinical trial of a dual-focus myopia control contact lens (MiSight 1 day) continued into a follow-on 1-year "wash-out" phase in which all subjects were fit with a single-vision contact lens (Proclear 1 day, omafilcon A; CooperVision, Inc.). Right and left eye data were analyzed from 38 subjects with 6 years of prior treatment (T6) and 40 receiving treatment during study years 4 to 6 (T3). Axial length and cyclopleged spherical equivalent refractive errors were monitored annually for 7 years. Expected axial growth and myopia progression during years 4 to 7 if treatment had not been started were estimated by extrapolating growth of untreated myopic control eyes collected during years 1 to 3 using population-based estimates of age effects on growth rates.

Results: During the untreated year 7, annualized axial growth and refractive changes were 0.09 ± 0.09 (T3) and 0.10 ± 0.10 mm/y (T6), and -0.23 ± 0.36 (T3) and -0.21 ± 0.40 D/y (T6), respectively, each slightly greater than observed during the previous year of treatment (0.07 ± 0.12 [T3] and 0.08 ± 0.07 mm [T6], and -0.04 ± 0.34 [T3] and -0.13 ± 0.42 D [T6]). Year 7 progression was less for the older (11 to 12 at baseline, -0.17 ± 0.40 D/0.05 ± 0.07 mm) than the younger (8 to 10 at baseline, -0.26 ± 0.36 D/0.13 ± 0.10 mm) subgroup. Years in treatment (3 vs. 6) did not influence post-treatment growth or progression.

Conclusions: A cessation study following 3 or 6 years of myopia control treatment with the dual-focus myopia control contact lens found axial growth and myopia progression rates similar to those expected of untreated myopic eyes at these ages. This finding reveals that accrued treatment gains were retained and neither amplified nor diminished after cessation of treatment.

查看原文本刊更多论文

停止使用双焦软性隐形眼镜控制近视治疗后的眼睛生长和近视进展。

意义：这项为期7年的临床研究评估了MiSight 1天(omafilcon A；CooperVision, Inc., Pleasanton， CA)双焦点隐形眼镜治疗后眼睛生长和近视进展。治疗后的生长和进展停止并恢复到正常年龄水平，保留了先前累积的治疗收益。目的：本研究旨在评估双焦隐形眼镜长期控制近视治疗结束后的眼睛生长和屈光变化。方法：83名受试者完成了为期6年的双焦控制近视隐形眼镜临床试验（MiSight 1天），并进入后续1年的“洗脱期”，在此期间，所有受试者均配戴单视力隐形眼镜(Proclear 1天，omafilcon a；CooperVision Inc .)。对38名受试者的右眼和左眼数据进行分析，其中38名受试者接受了6年的治疗（T6）， 40名受试者在研究4至6年（T3）期间接受了治疗。每年监测眼轴长度和单眼瘫痪的球面等效屈光不正7年。如果未开始治疗，则通过1至3年收集的未经治疗的近视对照眼的生长推断4至7年的预期轴向生长和近视进展，使用基于人群的年龄对生长速率的影响估计。结果：治疗第7年，眼轴生长和屈光变化的年化值分别为0.09±0.09 （T3）和0.10±0.10 mm/y (T6), -0.23±0.36 （T3）和-0.21±0.40 D/y (T6)，均略高于治疗前一年（0.07±0.12 [T3]和0.08±0.07 mm [T6], -0.04±0.34 [T3]和-0.13±0.42 D [T6]）。老年亚组（11 ~ 12岁，-0.17±0.40 D/0.05±0.07 mm）的第七年进展小于年轻亚组（8 ~ 10岁，-0.26±0.36 D/0.13±0.10 mm）。治疗时间（3年vs. 6年）不影响治疗后的生长或进展。结论：一项使用双焦控制近视隐形眼镜进行3年或6年近视控制治疗后的戒烟研究发现，这些年龄段的近视眼的轴向生长和近视进展率与未治疗的近视眼相似。这一发现表明，在停止治疗后，累积的治疗收益得以保留，既不扩大也不减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Optometry and Vision Science 医学-眼科学

CiteScore

2.80

自引率

7.10%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Optometry and Vision Science is the monthly peer-reviewed scientific publication of the American Academy of Optometry, publishing original research since 1924. Optometry and Vision Science is an internationally recognized source for education and information on current discoveries in optometry, physiological optics, vision science, and related fields. The journal considers original contributions that advance clinical practice, vision science, and public health. Authors should remember that the journal reaches readers worldwide and their submissions should be relevant and of interest to a broad audience. Topical priorities include, but are not limited to: clinical and laboratory research, evidence-based reviews, contact lenses, ocular growth and refractive error development, eye movements, visual function and perception, biology of the eye and ocular disease, epidemiology and public health, biomedical optics and instrumentation, novel and important clinical observations and treatments, and optometric education.